Valuation: Onconic Therapeutics Inc.

Market Cap 578B 375M 328M 301M 281M 532M 35.72B 541M 3.62B 1.4B 17.52B 1.41B 1.38B 60.36B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 525B 341M 298M 274M 255M 484M 32.47B 492M 3.29B 1.28B 15.92B 1.28B 1.25B 54.87B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.87%
Yield 2024 *
-
Yield 2025 -
1 day-7.01%
1 week-10.35%
Current month-5.35%
1 month-27.71%
3 months-44.65%
6 months-34.88%
Current year-34.88%
1 week 12,340
Extreme 12340
14,050
1 month 12,340
Extreme 12340
18,060
Current year 12,340
Extreme 12340
28,900
1 year 5,225
Extreme 5225
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2020
Director of Finance/CFO 50 01/01/2020
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 01/01/2020
Director/Board Member 59 01/01/2020
Director/Board Member 44 26/03/2024
Date Insider Type Main position Quantity % Market Cap.
22/04/25Fiscal year 50,000 0.4595%
18/04/25Fiscal year

Chief Technology Officer

12,500 0.1149%
17/04/25Fiscal year

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
-7.01%-10.35%+138.50% - 401M
+3.98%+10.23%+73.54%+132.19% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
-8.28%+8.28%-9.99%-9.62% 23.75B
+3.17%+6.82%+13.60%+437.83% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+9.85%+42.56%-27.36% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+6.76%+4.73%+25.85%+191.43% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +2.16%+6.67%+62.03%+146.33% 23.63B
Weighted average by Cap. +2.22%+6.08%+56.97%+135.91%

Financials

2024 2025
Net sales 14.84B 9.63M 8.42M 7.73M 7.21M 13.66M 917M 13.89M 93.04M 36.06M 450M 36.16M 35.38M 1.55B 53.39B 34.65M 30.28M 27.81M 25.93M 49.16M 3.3B 49.99M 335M 130M 1.62B 130M 127M 5.58B
Net income -8.09B -5.25M -4.59M -4.21M -3.93M -7.45M -500M -7.58M -50.74M -19.67M -245M -19.72M -19.29M -845M 15.78B 10.24M 8.95M 8.22M 7.67M 14.53M 975M 14.78M 98.97M 38.36M 478M 38.47M 37.63M 1.65B
Net Debt -42.69B -27.71M -24.21M -22.23M -20.73M -39.31M -2.64B -39.97M -268M -104M -1.29B -104M -102M -4.46B -52.61B -34.15M -29.84M -27.4M -25.55M -48.44M -3.25B -49.25M -330M -128M -1.59B -128M -125M -5.49B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
02/07/26 12,730.00 -7.01% 247,791
01/07/26 ₩13,690.00 +1.78% 170,827
30/06/26 ₩13,450.00 -3.93% 151,091
29/06/26 ₩14,000.00 +11.55% 359,436
26/06/26 ₩12,550.00 -10.16% 419,879
  1. Stock Market
  2. Stocks
  3. A476060 Stock